Pulmonology

A new pooled cohort analysis supports the longheld threshold of < .70 FEV1:FVC ratio to indicate patient risks from COPD-related events.

A new retrospective cohort finds that patients with untreated obstructive sleep apnea face a two-fold greater risk of developing T2D.

The FDA had previously only certified Symdeko tablets for treatment of children aged 12 years and older.

The endothelin receptor antagonist has proven benefits and safety for PAH patients burdened with liver or extrahepatic disease risks.

A three-arm clinical trial of the SAMBA program showed that screening for and tailoring to individuals' asthma needs improves their condition management.

New findings better evidence the link between long-term COPD exacerbations and poor patient sleep quality. How well-understood is the association between sleep and pulmonary conditions?

An assessment of the CanCOLD study showed that COPD exacerbations over 18 months were greater in patients with worse scores for sleep quality at baseline.

The rare, chronic condition requires investigators to turn to unique registries and other patient populations to access therapy benefits.

Overall rates of pulmonary rehabilitation rose in areas with greater program density, but rates for African Americans remained low despite greater program density.

The signs and symptoms of the rare, chronic condition are not consistently detected in the first line of care.

The real-world analysis of epicutaneous therapy for milk-related EoE progressively exposed pediatric patients to their milk allergen.

A new study from ATS showed an early symptom of Alzheimer disease is more prevalent in older patients with moderate OSA.

Neighborhoods redlined in the 1930s continue to feel the effects of the racially discriminatory practice, including differences in asthma-related emergency visits.

Sleep apnea is associated with pulmonary, cardiovascular, psychiatric, neurologic, and weight-related effects. Primary care physicians need to monitor sleep health more.

Previous analyses into MultiStem Cell Therapy have shown benefits and safety in stroke patients. What will it take for the therapy to reach a phase 3 trial for ARDS?

Within a week of treatment on the investigative biologic, patients with severe form of the condition were reporting a return of smell and taste.

Though the prostacyclin-targeting therapy selexipag is beneficial for PAH patients, investigators advise treatment to a trio of pathways.

Increased primary care use in a region was associated with reduced rates of ICU admission and mechanical ventilation use.

While 35% of providers say they’re unlikely to allow family to be present during ICU procedures, the 38% who say it’s a regular practice overwhelmingly call it a positive experience.

Why are major adverse cardiovascular events not treated as the concern risk factors they are in patients with obstructive sleep apnea?

Upper airway stimulation, a sleep apnea treatment on the rise, is showing particular benefit for female patients.

Early-stage study results from the multi-center MUST-ARDS trial show the ex-vivo adult progenitor cell-expanding therapy is capable of improving 28-day mortality, care burden, and overall safety in patients with ARDS.

Mental health disorders are highly prevalent in certain patients with COPD&mdash;and their effect can limit lung function therapy benefit.

Early research found that e-cigarette use affects the immune system response to the flu virus and the effects are different for female and male users.

A multivariate cohort showed opioids in situation of critical care may not drive rates of continued use after 1 year.